ADMA Biologics (NASDAQ:ADMA) Hits New 1-Year High at $6.97

ADMA Biologics, Inc. (NASDAQ:ADMA) shares hit a new 52-week high on Thursday . The stock traded as high as $6.97 and last traded at $6.95, with a volume of 1477602 shares. The stock had previously closed at $6.86.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ADMA shares. Mizuho upped their price target on ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald lifted their price target on ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, HC Wainwright restated a “buy” rating and set a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.88.

ADMA Biologics Stock Up 1.0 %

The firm has a 50 day simple moving average of $6.30 and a two-hundred day simple moving average of $5.07. The stock has a market capitalization of $1.58 billion, a P/E ratio of -52.77 and a beta of 0.43. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The company had revenue of $73.90 million during the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. On average, equities research analysts expect that ADMA Biologics, Inc. will post 0.3 earnings per share for the current year.

Insider Activity

In related news, Director Steve Elms sold 407,000 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the sale, the director now owns 3,208,671 shares of the company’s stock, valued at approximately $19,925,846.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 639,895 shares of company stock valued at $3,927,169 in the last ninety days. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in shares of ADMA Biologics during the third quarter valued at approximately $65,000. Commonwealth Equity Services LLC grew its stake in shares of ADMA Biologics by 61.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,360 shares of the biotechnology company’s stock worth $59,000 after buying an additional 6,250 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in ADMA Biologics by 31.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after buying an additional 3,572 shares during the last quarter. Raymond James & Associates lifted its position in ADMA Biologics by 4.3% in the 3rd quarter. Raymond James & Associates now owns 243,639 shares of the biotechnology company’s stock valued at $872,000 after acquiring an additional 10,018 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of ADMA Biologics by 71.3% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 248,477 shares of the biotechnology company’s stock worth $890,000 after purchasing an additional 103,464 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.